ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

LCTX vs OCGN // DIVIDEND YIELD & FCF PAYOUT SAFETY

Lineage Cell Therapeutics Inc. (NYSE) VS. Ocugen Inc. (NASDAQ) • 15-METRIC TALLY: LCTX 4 — OCGN 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LCTX VS. OCGN) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC LCTX OCGN SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -7.46% -22.65% +15.19 LCTX /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 53.20% 8.80% +44.40 LCTX /revenue-growth <GO>
Dividend Yield & FCF Payout Safety ACTIVE 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 3/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 54.9 34.7 +20.20 LCTX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $260.5M $252.4M $8.1M LCTX /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR LCTX REV OCGN REV LCTX GROSS % OCGN GROSS % LCTX FCF OCGN FCF
FY 2025 $14.6M $4.4M — — -$19.4M -$57.1M
FY 2024 $9.5M $4.1M 96.5% — -$23.7M -$45.5M
FY 2023 $8.9M $6.0M — — -$28.6M -$62.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LCTX // BETA —
OCGN // BETA —